Laser Interstitial Thermal Therapy Followed by Ultra Early Temozolomide for First Recurrent IDH Wild Type Glioblastoma: A Comparative Cohort Study With Prospective Enrolment and Retrospective Controls

Authors:
  • YZYutao Zhang
    Yutao Zhang
  • XZXuzhe Zhao
    Xuzhe Zhao
  • KWKai Wang
    Kai Wang
  • YWYong-Gang Wang
    Yong-Gang Wang
  • YWYinyan Wang
    Yinyan Wang
  • XRXiaohui Ren
    Xiaohui Ren
  • DZDabiao Zhou
    Dabiao Zhou

Abstract
Background: Evidence for laser interstitial thermal therapy (LITT) followed by ultra-early temozolomide at first recurrence of IDH-wild-type glioblastoma is limited. We assessed survival relative to nonsurgical management while accounting for measured treatment-selection differences. Methods: This single-centre comparative cohort study combined a prospective phase II LITT cohort (NCT05663125) with retrospective controls at Beijing Tiantan Hospital, China, during 2018–2024. Eligible patients were aged 18–75 years, had a first recurrence, and had Karnofsky Performance Status of at least 60. The complete-case cohort included 90 patients: ten receiving LITT, 43 surgery, and 37 nonsurgical management. Temozolomide began on postoperative day 2 after LITT. The primary overall survival comparison used LITT-focused propensity-score weighting targeting the average treatment effect on the treated. Secondary surgery analyses used overlap weighting; subgroup and PET/MR analyses were exploratory. Confidence intervals for 12-month restricted mean survival time differences were estimated with 10 000 stratified nonparametric bootstrap resamples, repeating propensity-score weighting within each resample. Findings: LITT plus ultra-early temozolomide was associated with longer survival than nonsurgical management (hazard ratio 0·31 [95% CI 0·13–0·77]; p=0·012). Twelve-month restricted mean survival was 305·95 versus 221·00 days, a difference of 84·95 days (percentile bootstrap 95% CI 4·67–173·28). The secondary surgery comparison yielded a hazard ratio of 0·39 (0·19–0·80; p=0·010) and a 12-month restricted mean survival difference of 54·54 days (−25·68 to 128·79). Insufficient common support precluded a reliable direct LITT–surgery comparison. PET/MR coverage was assessable in nine patients, with no statistically significant metric. Interpretation: LITT followed by ultra-early temozolomide was associated with longer survival in patients resembling the LITT cohort. The small, non-randomised study cannot establish causality or separate the contributions of LITT and temozolomide timing. Prospective comparative validation is needed.